Clinical effect of edaravone on treatment of patients with acute cerebral infarction and its influence on serum SOD and MDA

Obj ective To observe the clinical effect of edaravone on treatment of patients with acute cerebral infarction (ACI)and its influence on serum superoxide dismutase (SOD)and malondialdehyde (MDA).Methods A total of 64 ACI patients were randomly divided into control group (31 cases)treated with basic medicines and treatment group (33 cases)added with with edar-avone.Clinical efficacy,neurological function deficit improvement rate,American National Insti-tutes of Health Stroke Scale (NIHSS)and Barthel index (BI)as well as serum SOD and MDA level changes in both groups were observed.Results 14 d after treatment,the clinical efficacy in treat-ment group was 84.85%,significantly higher than the 61.29% in control group (P<0.01). NIHSS and Barthel scores were better after treatment than those before (P<0.01),and differences between two groups were also significant (P<0 .05 ).After treatment,SOD level was higher in treatment group (P<0 .0 1 )and lower in control group than those before treatment (P<0 .0 1 ), whereas MDA level was lower in treatment group (P<0 .0 1 )and higher in control group than those before treatment (P<0 .05 ).Additionally,there had no severe adverse responses in both groups. Conclusion On the basis of basic treatment,the application of edaravone has favorable clinical effi-cacy and safety in the treatment of ACI .